UY31981A - Oxazolopirimidinas como agonistas del receptor edg-1 - Google Patents
Oxazolopirimidinas como agonistas del receptor edg-1Info
- Publication number
- UY31981A UY31981A UY0001031981A UY31981A UY31981A UY 31981 A UY31981 A UY 31981A UY 0001031981 A UY0001031981 A UY 0001031981A UY 31981 A UY31981 A UY 31981A UY 31981 A UY31981 A UY 31981A
- Authority
- UY
- Uruguay
- Prior art keywords
- edg
- agonists
- compounds
- oxazolopirimidins
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos de oxazolopirimidina de la fórmula I en la que A, R1, R2 y R3 se definen como se ha indicado en las reivindicaciones. Los compuestos de la fórmula I modulan la actividad del receptor Edg-1 y son agonistas de este receptor, y son útiles para el tratamiento de aterosclerosis, fallo cardíaco o enfermedad oclusiva de las arterias periféricas, por ejemplo. la invención se refiere a procesos para la preparación de dichos compuestos, a su uso, como ingredientes activos en productos farmacéuticos, y a composiciones farmacéuticas que los contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290694 | 2008-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31981A true UY31981A (es) | 2010-02-26 |
Family
ID=39967817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001031981A UY31981A (es) | 2008-07-15 | 2009-07-13 | Oxazolopirimidinas como agonistas del receptor edg-1 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8735387B2 (es) |
EP (2) | EP2583720A1 (es) |
JP (1) | JP5449346B2 (es) |
KR (1) | KR20110042286A (es) |
CN (1) | CN102159582B (es) |
AR (1) | AR072496A1 (es) |
AU (1) | AU2009270511B2 (es) |
BR (1) | BRPI0915781A2 (es) |
CA (1) | CA2730843A1 (es) |
CL (1) | CL2011000071A1 (es) |
CO (1) | CO6331436A2 (es) |
IL (1) | IL210639A0 (es) |
MA (1) | MA32455B1 (es) |
MX (1) | MX2011000211A (es) |
NZ (1) | NZ590377A (es) |
RU (1) | RU2503680C2 (es) |
TW (1) | TW201016707A (es) |
UY (1) | UY31981A (es) |
WO (1) | WO2010006704A1 (es) |
ZA (1) | ZA201008786B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33177A (es) | 2010-01-13 | 2011-08-31 | Sanofi Aventis | Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido |
UY33176A (es) | 2010-01-13 | 2011-08-31 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2, 5, 7. |
PT2523960E (pt) * | 2010-01-14 | 2013-12-09 | Sanofi Sa | Derivados heterocíclicos de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5 |
EP2523962B1 (de) | 2010-01-14 | 2013-11-27 | Sanofi | Carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring |
SG182483A1 (en) * | 2010-01-14 | 2012-08-30 | Sanofi Sa | 2,5-substituted oxazolopyrimidine derivatives |
WO2011111831A1 (ja) | 2010-03-12 | 2011-09-15 | 日本曹達株式会社 | ピリジン環含有化合物、及びハロゲン化ピコリン誘導体及びテトラゾリルオキシム誘導体の製造方法 |
US8907093B2 (en) | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
US9321787B2 (en) | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
US8735402B2 (en) * | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
EP3632919B1 (en) * | 2012-04-26 | 2022-10-26 | Bristol-Myers Squibb Company | Pharmaceutical compoisitions comprising imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
ES2625029T3 (es) * | 2012-04-26 | 2017-07-18 | Bristol-Myers Squibb Company | Derivados del imidazotiadiazol como inhibidores del receptor 4 activado por proteasa (Par4) para el tratamiento de la agregación de plaquetas |
EP3297990A4 (en) | 2015-03-26 | 2019-01-23 | The Florey Institute Of Neuroscience And Mental Health | MODULATORS OF SODIUM CHANNELS |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3679682A (en) * | 1970-04-23 | 1972-07-25 | Fmc Corp | CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES |
JP4155827B2 (ja) * | 2001-05-14 | 2008-09-24 | ノバルティス アクチエンゲゼルシャフト | オキサゾロ−およびフロピリミジンならびに腫瘍に対する医薬としてのその使用 |
AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
CA2523739A1 (en) | 2003-04-25 | 2004-11-11 | University College Cardiff Consultants Limited | Heterocyclic compounds for use in the treatment of viral infections |
MXPA05011597A (es) * | 2003-04-30 | 2005-12-15 | Novartis Ag | Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. |
US7417065B2 (en) * | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
US20070027156A1 (en) | 2003-09-09 | 2007-02-01 | Hisao Nakai | Crf antagonists and heterobicyclic compounds |
US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
WO2005067546A2 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
CA2630714C (en) * | 2005-11-23 | 2014-01-14 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
EP1900729A1 (en) * | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
-
2009
- 2009-07-02 NZ NZ590377A patent/NZ590377A/en not_active IP Right Cessation
- 2009-07-02 JP JP2011517773A patent/JP5449346B2/ja not_active Expired - Fee Related
- 2009-07-02 US US13/003,125 patent/US8735387B2/en not_active Expired - Fee Related
- 2009-07-02 BR BRPI0915781A patent/BRPI0915781A2/pt not_active IP Right Cessation
- 2009-07-02 RU RU2011105388/04A patent/RU2503680C2/ru not_active IP Right Cessation
- 2009-07-02 WO PCT/EP2009/004770 patent/WO2010006704A1/en active Application Filing
- 2009-07-02 AU AU2009270511A patent/AU2009270511B2/en not_active Ceased
- 2009-07-02 EP EP13151034.9A patent/EP2583720A1/en not_active Withdrawn
- 2009-07-02 MX MX2011000211A patent/MX2011000211A/es active IP Right Grant
- 2009-07-02 KR KR1020117001113A patent/KR20110042286A/ko not_active Application Discontinuation
- 2009-07-02 EP EP09776914A patent/EP2318415B1/en active Active
- 2009-07-02 CN CN200980135883.4A patent/CN102159582B/zh not_active Expired - Fee Related
- 2009-07-02 CA CA2730843A patent/CA2730843A1/en not_active Abandoned
- 2009-07-13 UY UY0001031981A patent/UY31981A/es not_active Application Discontinuation
- 2009-07-13 TW TW098123561A patent/TW201016707A/zh unknown
- 2009-07-13 AR ARP090102624A patent/AR072496A1/es not_active Application Discontinuation
-
2010
- 2010-12-07 ZA ZA2010/08786A patent/ZA201008786B/en unknown
-
2011
- 2011-01-05 MA MA33493A patent/MA32455B1/fr unknown
- 2011-01-12 CL CL2011000071A patent/CL2011000071A1/es unknown
- 2011-01-13 IL IL210639A patent/IL210639A0/en unknown
- 2011-01-14 CO CO11003596A patent/CO6331436A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA32455B1 (fr) | 2011-07-03 |
TW201016707A (en) | 2010-05-01 |
ZA201008786B (en) | 2012-01-25 |
RU2011105388A (ru) | 2012-08-20 |
CO6331436A2 (es) | 2011-10-20 |
BRPI0915781A2 (pt) | 2015-11-10 |
WO2010006704A1 (en) | 2010-01-21 |
US20110190490A1 (en) | 2011-08-04 |
CA2730843A1 (en) | 2010-01-21 |
MX2011000211A (es) | 2011-03-03 |
IL210639A0 (en) | 2011-03-31 |
US8735387B2 (en) | 2014-05-27 |
JP5449346B2 (ja) | 2014-03-19 |
KR20110042286A (ko) | 2011-04-26 |
CN102159582A (zh) | 2011-08-17 |
AU2009270511A1 (en) | 2010-01-21 |
EP2318415B1 (en) | 2013-02-20 |
CL2011000071A1 (es) | 2011-05-06 |
RU2503680C2 (ru) | 2014-01-10 |
JP2011527994A (ja) | 2011-11-10 |
EP2318415A1 (en) | 2011-05-11 |
CN102159582B (zh) | 2014-05-07 |
AU2009270511B2 (en) | 2013-07-18 |
EP2583720A1 (en) | 2013-04-24 |
AR072496A1 (es) | 2010-09-01 |
NZ590377A (en) | 2011-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31981A (es) | Oxazolopirimidinas como agonistas del receptor edg-1 | |
UY31351A1 (es) | (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos | |
UY33485A (es) | Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos. | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
ECSP10010615A (es) | Derivados de benzofurano, benzotiofeno, benzotiazol como moduladores de fxr | |
UY31651A1 (es) | Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos. | |
UY29839A1 (es) | Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones. | |
CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY29300A1 (es) | Compuestos quimicos | |
DOP2013000130A (es) | Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2 | |
UY31350A1 (es) | (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos | |
CU20130082A7 (es) | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr | |
UY30481A1 (es) | Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos. | |
UY29223A1 (es) | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
CU20120099A7 (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
CO6680683A2 (es) | Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias | |
PA8622401A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos | |
CL2008000806A1 (es) | Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras. | |
PA8842101A1 (es) | Heteroarilos sustituidos | |
AR081774A1 (es) | Composiciones farmaceuticas de co-cristales de tramadol y coxibs | |
UY30094A1 (es) | Compuestos químicos | |
UY32502A (es) | Agentes antihelmínticos y su utilización | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
ECSP13012600A (es) | CO-cristales y Sales de Inhibidores de CCR3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20140519 |